• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

放疗联合免疫治疗宫颈癌:现状与未来

Combining Radiotherapy with Immunotherapy in Cervical Cancer: Where Do We Stand and Where Are We Going?

机构信息

Department of Obstetrics, Shenzhen Longhua District Central Hospital, Shenzhen, 518110, China.

Department of General Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, 518110, China.

出版信息

Curr Treat Options Oncol. 2023 Oct;24(10):1378-1391. doi: 10.1007/s11864-023-01128-6. Epub 2023 Aug 3.

DOI:10.1007/s11864-023-01128-6
PMID:37535254
Abstract

Combining immunotherapy and radiotherapy as a treatment strategy for cervical cancer has attracted increasing attention. The primary objective of this review is to provide an up-to-date summary of the knowledge regarding the combined use of radiotherapy and immunotherapy for treating cervical cancer. This review discusses the biological rationale combining immunotherapy with radiotherapy in a clinical setting and presents supporting evidence for the combination strategy based on both safety and effectiveness data. Additionally, we discuss the potential and challenges of combining radiotherapy and immunotherapy in clinical practice.

摘要

将免疫疗法与放射疗法相结合作为宫颈癌的治疗策略已引起广泛关注。本文旨在对放疗联合免疫治疗宫颈癌的相关知识进行综述。本文讨论了在临床环境中联合使用免疫疗法和放射疗法的生物学原理,并根据安全性和有效性数据为联合治疗策略提供了支持证据。此外,本文还讨论了在临床实践中联合应用放疗和免疫疗法的潜力和挑战。

相似文献

1
Combining Radiotherapy with Immunotherapy in Cervical Cancer: Where Do We Stand and Where Are We Going?放疗联合免疫治疗宫颈癌:现状与未来
Curr Treat Options Oncol. 2023 Oct;24(10):1378-1391. doi: 10.1007/s11864-023-01128-6. Epub 2023 Aug 3.
2
Current Status of Clinical Trials for Cervical and Uterine Cancer Using Immunotherapy Combined With Radiation.免疫治疗联合放疗治疗宫颈癌和子宫内膜癌的临床试验现状。
Int J Radiat Oncol Biol Phys. 2021 Feb 1;109(2):396-412. doi: 10.1016/j.ijrobp.2020.09.016. Epub 2020 Sep 15.
3
[Effect of 5'-DFUR used concurrently in radiotherapy and immunotherapy uterine cervical cancer--pilot study. Study of 5'-DFUR for Uterine Cervical Cancer].5'-去氧氟尿苷同步用于子宫颈癌放疗和免疫治疗的效果——初步研究。5'-去氧氟尿苷治疗子宫颈癌的研究
Gan To Kagaku Ryoho. 1998 Apr;25(5):705-11.
4
Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies.免疫治疗联合放疗治疗泌尿生殖系统恶性肿瘤。
Eur Urol Oncol. 2019 Feb;2(1):79-87. doi: 10.1016/j.euo.2018.09.013. Epub 2018 Nov 16.
5
Current and potential treatments for cervical cancer.宫颈癌的当前和潜在治疗方法。
Curr Cancer Drug Targets. 2013 Feb;13(2):205-20. doi: 10.2174/1568009611313020009.
6
The Role of Biomarkers for the Prediction of Response to Checkpoint Immunotherapy and the Rationale for the Use of Checkpoint Immunotherapy in Cervical Cancer.生物标志物在预测免疫检查点治疗反应中的作用及在宫颈癌中应用免疫检查点治疗的原理。
Clin Oncol (R Coll Radiol). 2019 Dec;31(12):834-843. doi: 10.1016/j.clon.2019.07.003. Epub 2019 Jul 19.
7
The role of radiotherapy in the age of immunotherapy.放疗在免疫治疗时代的作用。
Jpn J Clin Oncol. 2021 Apr 1;51(4):513-522. doi: 10.1093/jjco/hyaa268.
8
Immunotherapy With Radiotherapy and Chemoradiotherapy for Cervical Cancer.宫颈癌的放化疗免疫治疗。
Semin Radiat Oncol. 2020 Oct;30(4):273-280. doi: 10.1016/j.semradonc.2020.05.003.
9
Immunotherapy and Radiation Therapy in Renal Cell Carcinoma.免疫治疗与肾细胞癌的放射治疗。
Curr Drug Targets. 2020;21(14):1463-1475. doi: 10.2174/1389450121666200311121540.
10
The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge.抗 PD-1 时代的宫颈癌:成就、机遇和挑战。
Front Immunol. 2023 Jul 25;14:1195476. doi: 10.3389/fimmu.2023.1195476. eCollection 2023.

引用本文的文献

1
Mitochondrial Quality Control Systems in Septic AKI: Molecular Mechanisms and Therapeutic Implications.脓毒症急性肾损伤中的线粒体质量控制系统:分子机制与治疗意义
Int J Med Sci. 2025 Mar 19;22(8):1852-1864. doi: 10.7150/ijms.107012. eCollection 2025.
2
Identifying Water-Salt Homeostasis and Inflammatory Response in Pathological Cardiac Surgery-Associated Acute Kidney Injury: NT-proBNP-related lncRNAs and miRNAs as Novel Diagnostic Biomarkers and Therapeutic Targets.识别病理心脏手术相关急性肾损伤中的水盐稳态和炎症反应:NT-proBNP相关长链非编码RNA和微小RNA作为新型诊断生物标志物和治疗靶点
Int J Med Sci. 2025 Jan 21;22(4):845-855. doi: 10.7150/ijms.107589. eCollection 2025.
3

本文引用的文献

1
MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors.电影:一项 I 期、开放性、多中心研究,旨在评估节拍式长春瑞滨联合度伐利尤单抗和替西木单抗治疗晚期实体瘤患者的安全性和耐受性。
ESMO Open. 2022 Dec;7(6):100646. doi: 10.1016/j.esmoop.2022.100646. Epub 2022 Dec 13.
2
Radiotherapy combined with immunotherapy: the dawn of cancer treatment.放疗联合免疫治疗:癌症治疗的曙光。
Signal Transduct Target Ther. 2022 Jul 29;7(1):258. doi: 10.1038/s41392-022-01102-y.
3
Association of Cell Death Markers With Tumor Immune Cell Infiltrates After Chemo-Radiation in Cervical Cancer.
Unveiling the role of risk factors and predictive models in acute type-a aortic dissection surgery: OI downregulation and its association with immune disorders.
揭示危险因素和预测模型在急性A型主动脉夹层手术中的作用:OI下调及其与免疫紊乱的关联。
Int J Med Sci. 2025 Jan 13;22(3):745-753. doi: 10.7150/ijms.104622. eCollection 2025.
4
Glycosphingolipids-Dependent Phospholipid Metabolism Enhances Cancer Initiation and Progression through SMPD1/GLTP/B3GALT4/ST8SIA6 Signaling Axis: A Novel Therapeutic Target.糖鞘脂依赖性磷脂代谢通过SMPD1/GLTP/B3GALT4/ST8SIA6信号轴增强癌症起始和进展:一个新的治疗靶点。
Int J Med Sci. 2025 Jan 6;22(3):604-615. doi: 10.7150/ijms.103834. eCollection 2025.
5
Spinal Metastasis Pain Surveillance: A Comprehensive Imaging-Based Tool Design for Evaluating Metastatic Burden and Guiding Therapeutic Strategies.脊柱转移瘤疼痛监测:一种基于影像学的综合工具设计,用于评估转移负担和指导治疗策略。
Int J Med Sci. 2025 Jan 13;22(3):708-715. doi: 10.7150/ijms.103916. eCollection 2025.
6
Efficacy and safety of chemoradiotherapy plus immune checkpoint inhibitors for the treatment of locally advanced cervical cancer: a systematic review and meta-analysis.放化疗联合免疫检查点抑制剂治疗局部晚期宫颈癌的疗效和安全性:系统评价和荟萃分析。
Front Immunol. 2024 Sep 16;15:1459693. doi: 10.3389/fimmu.2024.1459693. eCollection 2024.
7
Identifying hub genes for chemo-radiotherapy sensitivity in cervical cancer: a bi-dataset in silico analysis.识别宫颈癌放化疗敏感性的枢纽基因:一项基于双数据集的计算机分析
Discov Oncol. 2024 Sep 12;15(1):434. doi: 10.1007/s12672-024-01328-y.
8
Advancements in melanoma immunotherapy: the emergence of Extracellular Vesicle Vaccines.黑色素瘤免疫疗法的进展:细胞外囊泡疫苗的出现。
Cell Death Discov. 2024 Aug 23;10(1):374. doi: 10.1038/s41420-024-02150-9.
9
Current landscape of exosomes in tuberculosis development, diagnosis, and treatment applications.外泌体在结核病发展、诊断和治疗应用中的研究现状。
Front Immunol. 2024 May 23;15:1401867. doi: 10.3389/fimmu.2024.1401867. eCollection 2024.
10
Investigating the Use of a Liquid Immunogenic Fiducial Eluter Biomaterial in Cervical Cancer Treatment.研究液体免疫原性基准洗脱生物材料在宫颈癌治疗中的应用。
Cancers (Basel). 2024 Mar 20;16(6):1212. doi: 10.3390/cancers16061212.
宫颈癌放化疗后细胞死亡标志物与肿瘤免疫细胞浸润的关联
Front Oncol. 2022 Jul 12;12:892813. doi: 10.3389/fonc.2022.892813. eCollection 2022.
4
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826.帕博利珠单抗联合化疗治疗持续性、复发性或转移性宫颈癌的日本患者:KEYNOTE-826 研究结果。
Cancer Sci. 2022 Nov;113(11):3877-3887. doi: 10.1111/cas.15479. Epub 2022 Sep 15.
5
Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response.MHC-I 下调的机制及其在免疫治疗反应中的作用。
Front Immunol. 2022 Feb 28;13:844866. doi: 10.3389/fimmu.2022.844866. eCollection 2022.
6
DNA Damage and Activation of cGAS/STING Pathway Induce Tumor Microenvironment Remodeling.DNA损伤与cGAS/STING通路激活诱导肿瘤微环境重塑。
Front Cell Dev Biol. 2022 Feb 21;9:828657. doi: 10.3389/fcell.2021.828657. eCollection 2021.
7
Global challenges of radiotherapy for the treatment of locally advanced cervical cancer.局部晚期宫颈癌放射治疗的全球挑战。
Int J Gynecol Cancer. 2022 Mar;32(3):436-445. doi: 10.1136/ijgc-2021-003001.
8
Advances in immunotherapy for cervical cancer: recent developments and future directions.宫颈癌免疫治疗的进展:最新发展与未来方向
Int J Gynecol Cancer. 2022 Mar;32(3):281-287. doi: 10.1136/ijgc-2021-002492.
9
Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial.信迪利单抗联合安罗替尼治疗 PD-L1 阳性复发性或转移性宫颈癌的有效性和安全性:一项多中心、单臂、前瞻性 II 期试验。
J Clin Oncol. 2022 Jun 1;40(16):1795-1805. doi: 10.1200/JCO.21.02091. Epub 2022 Feb 22.
10
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.